SubHero Banner
Text

Faslodex® (fulvestrant) – Expanded indication

August 28, 2107 – AstraZeneca announced the FDA approval of Faslodex (fulvestrant) injection, for the treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.

Download PDF